Sanofi secures China approval for Tzield as first disease-modifying therapy for stage 2 type 1 diabetes

Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA

Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles

Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome

AMO Pharma signs licence agreement with PHRI and Venca Research Inc to advance new study in ARVC

Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD

Phanes Therapeutics reports first BTC patient dosed in trial of spevatamig in combination with chemotherapy

Amgen and Kyowa Kirin release rocatinlimab study results in atopic dermatitis

Hemogenyx Pharmaceuticals partners with Made Scientific to advance CAR-T therapy

Lilly's Jaypirca delivers breakthrough results in front-line CLL trial

Anixa Biosciences completes dosing of fourth cohort in ovarian cancer CAR-T trial; Early results show promise

Johnson & Johnson's Phase 3 MARIPOSA study shows RYBREVANT and LAZCLUZE prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer

BioMarin reveals positive PALYNZIQ (pegvaliase-pqpz) Phase 3 data in adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism

Nuvalent presents zidesamtinib ARROS-1 clinical trial data for TKI Pre-treated patients with Advanced ROS1-positive NSCLC at WCLC 2025

IDEAYA Biosciences and Hengrui Pharma announce IDE849 (SHR-4849) positive Phase 1 data in small cell lung cancer at IASLC 2025 World Conference on Lung Cancer